27 May 2022
Covid-19 vaccines: authorised – Jcovden (previously Covid-19 Vaccine Janssen)
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) approved a new manufacturing site for Covid-19 Jcovden. Jcovden is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 18 years and older. Jcovden is made up of another virus that has been modified to contain the gene for making a protein found on SARS-CoV-2.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar